Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.75 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.74 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | PRKDC | P78527 | 2/20 | 0.59 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24519480 | 0.91 | MTOR (0.75) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL20553464 | 0.89 | MTOR (0.61) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL30325024 | 0.88 | MTOR (0.82) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL19282991 | 0.88 | MTOR (0.82) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL19294568 | 0.88 | MTOR (0.69) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL29939161 | 0.88 | MTOR (0.69) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL25113527 | 0.88 | MTOR (0.72) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL23150430 | 0.87 | MTOR (0.70) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL20553596 | 0.87 | MTOR (0.75) | MTORHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL29669811 | 0.87 | MTOR (0.75) | MTORHDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066134-A1 | mTORC1 INHIBITORS | UNIV CALIFORNIA (US) | 2024-02-29 | — | — | US | disclosed |
| US-20210052735-A1 | mTORC1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-02-25 | — | — | US | disclosed |
| US-10646577-B2 | mTORC1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190091340-A1 | mTORC1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-28 | — | — | US | disclosed |
| US-10117945-B2 | mTORC1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170246305-A1 | mTORC1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052735-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
| US-20240066134-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
| US-20190091340-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
| US-20170246305-A1 | mTORC1 INHIBITORS | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
| US-10117945-B2 | mTORC1 inhibitors | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
| US-10646577-B2 | mTORC1 inhibitors | MTOR, RPTOR, RICTOR | MTOR 1/4885HDAC1 198/4885HDAC3 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.